Resultados da busca - Matthew B. Rettig

Refinar Resultados
  1. 1
    Mechanism of von Hippel-Lindau Protein-Mediated Suppression of Nuclear Factor kappa B Activity

    Mechanism of von Hippel-Lindau Protein-Mediated Suppression of Nuclear Factor kappa B Activity por Jiabin An, Matthew B. Rettig

    Publicado em 2005
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  2. 2
    The Kaposi sarcoma–associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element

    The Kaposi sarcoma–associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element por Jiabin An, Alan Lichtenstein, Gregory A. Brent, Matthew B. Rettig

    Publicado em 2002
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    NF-κB–Dependent Plasticity of the Epithelial to Mesenchymal Transition Induced by <i>Von Hippel-Lindau</i> Inactivation in Renal Cell Carcinomas

    NF-κB–Dependent Plasticity of the Epithelial to Mesenchymal Transition Induced by <i>Von Hippel-Lindau</i> Inactivation in Renal Cell Carcinomas por Allan J. Pantuck, Jiabin An, Huiren Liu, Matthew B. Rettig

    Publicado em 2010
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain

    Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain por N. G. R. Dayan Elshan, Matthew B. Rettig, Michael E. Jung

    Publicado em 2018
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  5. 5
    Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?

    Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough? por Daniel Vargas Pivato de Almeida, Lawrence Fong, Matthew B. Rettig, Karen A. Autio

    Publicado em 2020
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  6. 6
    Inactivation of the CYLD Deubiquitinase by HPV E6 Mediates Hypoxia-Induced NF-κB Activation

    Inactivation of the CYLD Deubiquitinase by HPV E6 Mediates Hypoxia-Induced NF-κB Activation por Jiabin An, Deqiong Mo, Huiren Liu, Mysore S. Veena, Eri S. Srivatsan, Ramin Massoumi, Matthew B. Rettig

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    Hyperactivated JNK Is a Therapeutic Target in pVHL-Deficient Renal Cell Carcinoma

    Hyperactivated JNK Is a Therapeutic Target in pVHL-Deficient Renal Cell Carcinoma por Jiabin An, Huiren Liu, Clara E. Magyar, Yanchuan Guo, Mysore S. Veena, Eri S. Srivatsan, Jiaoti Huang, Matthew B. Rettig

    Publicado em 2013
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression

    AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression por Joseph Gera, Ingo K. Mellinghoff, Yijiang Shi, Matthew B. Rettig, Chris Tran, Jung-Hsin Hsu, Charles L. Sawyers, Alan Lichtenstein

    Publicado em 2004
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  9. 9
    Enhanced Chemoprevention of Prostate Cancer by Combining Arctigenin with Green Tea and Quercetin in Prostate-Specific Phosphatase and Tensin Homolog Knockout Mice

    Enhanced Chemoprevention of Prostate Cancer by Combining Arctigenin with Green Tea and Quercetin in Prostate-Specific Phosphatase and Tensin Homolog Knockout Mice por Qiongyu Hao, Susanne M. Henning, Clara E. Magyar, Jonathan W. Said, Jin Zhong, Matthew B. Rettig, Jaydutt V. Vadgama, Piwen Wang

    Publicado em 2024
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease

    A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease por James R. Berenson, Robert Vescio, Kathryn Henick, Carol Y. Nishikubo, Matthew B. Rettig, Regina A. Swift, Francisco Conde, Joseph M. Von Teichert

    Publicado em 2001
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  11. 11
    Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting

    Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting por Kerstin Johnsson, Johan Brynolfsson, Hannicka Sahlstedt, Nicholas G. Nickols, Matthew B. Rettig, Stephan Probst, Michael J. Morris, Anders Bjartell, M. Eiber, Aseem Anand

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  12. 12
    aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in <sup>18</sup>F-DCFPyL Images of Veterans with Prostate Cancer

    aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in <sup>18</sup>F-DCFPyL Images of Veterans with Prostate Cancer por Nicholas G. Nickols, Aseem Anand, Kerstin Johnsson, Johan Brynolfsson, Pablo Borreli, Neil R. Parikh, Jesus E. Juarez, Lida Jafari, Mattias Eiber, Matthew B. Rettig

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  13. 13
    Impact of PSMA PET on Prostate Cancer Management

    Impact of PSMA PET on Prostate Cancer Management por Adam B. Weiner, Raag Agrawal, Luca Valle, Ida Sonni, Amar U. Kishan, Matthew B. Rettig, Steven S. Raman, Jérémie Calais, Paul C. Boutros, Robert E. Reiter

    Publicado em 2024
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  14. 14
    Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo

    Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo por Maryam Sartippour, Navindra P. Seeram, Jian Yu Rao, Aune Moro, Diane Harris, Susanne M. Henning, Amita Firouzi, Matthew B. Rettig, William J. Aronson, Allan J. Pantuck, David Heber

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  15. 15
    Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study

    Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study por Ida Sonni, Matthias Eiber, Wolfgang P. Fendler, Rejah M. Alano, Sitaram S. Vangala, Amar U. Kishan, Nicholas G. Nickols, Matthew B. Rettig, Robert E. Reiter, Johannes Czernin, Jérémie Calais

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  16. 16
    Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-κB-dependent mechanism

    Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-κB-dependent mechanism por Matthew B. Rettig, David Heber, Jiabin An, Navindra P. Seeram, Jian Yu Rao, Huiren Liu, Tobias Klatte, Arie S. Belldegrun, Aune Moro, Susanne M. Henning, Deqiong Mo, William J. Aronson, Allan J. Pantuck

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  17. 17
    Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology

    Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology por Corinne Renier, Edward Pao, James Che, Haiyan E. Liu, Clementine A. Lemaire, Melissa Matsumoto, Melanie Triboulet, Sandy Srivinas, Stefanie S. Jeffrey, Matthew B. Rettig, Rajan P. Kulkarni, Dino Di Carlo, Elodie Sollier‐Christen

    Publicado em 2017
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  18. 18
    Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

    Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer por Bruce Montgomery, Mario A. Eisenberger, Matthew B. Rettig, Franklin Chu, Роберто Пили, Joseph J. Stephenson, Nicholas J. Vogelzang, Alan J. Koletsky, Luke T. Nordquist, William J. Edenfield, Khalid Mamlouk, Karen J. Ferrante, Mary-Ellen Taplin

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  19. 19
    PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging

    PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging por Adrien Holzgreve, Wesley R. Armstrong, Kevyn J Clark, Matthias Benz, Clayton Smith, Loïc Djaileb, Andrei Gafita, Pan Thin, Nicholas G. Nickols, Amar U. Kishan, Matthew B. Rettig, Robert E. Reiter, Johannes Czernin, Jérémie Calais

    Publicado em 2025
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  20. 20
    Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer

    Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer por Katharina Lückerath, Wei Liu, Wolfgang P. Fendler, Susan Evans‐Axelsson, Andreea D. Stuparu, Roger Slavik, Christine E. Mona, Jérémie Calais, Matthew B. Rettig, Robert E. Reiter, Ken Herrmann, Caius G. Radu, Johannes Czernin, Matthias Eiber

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: